Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Scilex Holding Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Scilex Holding's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 9.4% per year.
Anahtar bilgiler
-9.0%
Kazanç büyüme oranı
-17.8%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | 9.4% |
| Özkaynak getirisi | n/a |
| Net Marj | -337.4% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically
Jun 14
It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks
Apr 24Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues
Feb 28Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)
Dec 21Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings
May 06Gelir ve Gider Dağılımı
Scilex Holding nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 51 | -172 | 118 | 12 |
| 31 Mar 24 | 47 | -161 | 120 | 13 |
| 31 Dec 23 | 47 | -167 | 120 | 13 |
| 30 Sep 23 | 45 | -163 | 120 | 13 |
| 30 Jun 23 | 46 | -54 | 95 | 10 |
| 31 Mar 23 | 42 | -45 | 83 | 9 |
| 31 Dec 22 | 38 | -23 | 65 | 9 |
| 30 Sep 22 | 34 | -47 | 56 | 9 |
| 30 Jun 22 | 31 | -81 | 51 | 9 |
| 31 Mar 22 | 33 | -78 | 49 | 9 |
| 31 Dec 21 | 31 | -88 | 51 | 9 |
| 31 Dec 20 | 24 | -48 | 43 | 10 |
| 31 Dec 19 | 21 | -179 | 65 | 10 |
Kaliteli Kazançlar: SCLX is currently unprofitable.
Büyüyen Kar Marjı: SCLX is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: SCLX is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
Büyüme Hızlandırma: Unable to compare SCLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: SCLX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Özkaynak Getirisi
Yüksek ROE: SCLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.